Bosh sahifaATAI • NASDAQ
add
ATAI Life Sciences NV
1,52 $
Seans yopilganidan keyin:(1,97%)+0,030
1,55 $
Yopilgan:23-apr, 17:13:47 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
1,47 $
Kunlik diapazon
1,43 $ - 1,56 $
Yillik diapazon
1,03 $ - 2,57 $
Bozor kapitalizatsiyasi
303,69 mln USD
Oʻrtacha hajm
1,70 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | -5,00 ming | -127,78% |
Joriy xarajat | 29,34 mln | -12,62% |
Sof foyda | -38,96 mln | -112,98% |
Sof foyda marjasi | 779,16 ming | 866,72% |
Har bir ulushga tushum | -0,24 | -100,00% |
EBITDA | -29,12 mln | 12,97% |
Amaldagi soliq stavkasi | 1,81% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 62,33 mln | -65,23% |
Jami aktivlari | 159,39 mln | -45,69% |
Jami passivlari | 42,83 mln | -12,87% |
Umumiy kapital | 116,55 mln | — |
Tarqatilgan aksiyalar | 198,31 mln | — |
Narxi/balansdagi bahosi | 2,13 | — |
Aktivlardan daromad | -41,11% | — |
Kapitaldan daromad | -46,44% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -38,96 mln | -112,98% |
Operatsiyalardan naqd pul | -24,30 mln | -10,62% |
Sarmoyadan naqd pul | 6,56 mln | 897,08% |
Moliyadan naqd pul | 154,00 ming | 101,82% |
Naqd pulning sof oʻzgarishi | -17,46 mln | 44,50% |
Boʻsh pul | -1,72 mln | 86,74% |
Haqida
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Tashkil etilgan
2018
Sayt
Xodimlar soni
54
